Allison Bratzel
Stock Analyst at Piper Sandler
(1.88)
# 1091
Out of 5,329 analysts
38
Total ratings
64.29%
Success rate
19.45%
Average return
Main Sectors:
Top Industries:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
RARE Ultragenyx Pharmaceu... | Maintains: Overweight | 140 115 | 38.96 | 195.17% | 1 | Mar 17, 2025 | |
AKBA Akebia Therapeutics | Maintains: Overweight | 4 6 | 2.4 | 150% | 1 | Mar 14, 2025 | |
INZY Inozyme Pharma | Maintains: Overweight | 30 23 | 1.2 | 1816.67% | 1 | Mar 11, 2025 | |
ENGN enGene Holdings | Initiates Coverage On: Overweight | 26 | 3.65 | 612.33% | 1 | Feb 18, 2025 | |
ARGX argenx | Maintains: Overweight | 620 725 | 638.88 | 13.48% | 13 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 12 22 | 20.81 | 5.72% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 15 23 | 18.79 | 22.41% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 65 62 | 31.79 | 95.03% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 42 | 32.84 | 27.89% | 3 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 22 | 11.59 | 89.82% | 2 | Jul 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 4 4 | 1.4 | 185.71% | 2 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 8 20 | 3.66 | 446.45% | 4 | Mar 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 20 | 2.5 | 700% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 23 25 | n/a | n/a | 1 | Apr 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Assumes: Overweight | 44 | 9.66 | 355.49% | 1 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 | 62.09 | 61.06% | 2 | Feb 8, 2023 |